Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

Journal of psychopharmacology (Oxford, England) - 1 Mar 2012

Cutler Jessica A, Rush A John, McMahon Francis J, Laje Gonzalo

Abstract excerpt

The essential amino acid tryptophan is the precursor to serotonin, but it can also be metabolized into kynurenine through indoleamine-2,3-dioxygenase (IDO). Increased immune activation has long been associated with symptoms of depression and has been shown to upregulate the expression of IDO. The presence of additional IDO directs more tryptophan down the kynurenine pathway, leaving less available for synthesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Citalopram

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Diagnostic and Statistical Manual of Mental Disorders

Share to Indoleamine-Pyrrole 2,3,-Dioxygenase

Share to Psychiatric Status Rating Scales

Share to Remission Induction

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 22282879
DOI: 10.1177/0269881111434622

Genes

IDO2
IDO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.PMID 22282879Read ↗

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Semantic proximity Read ↗

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.Semantic proximity Read ↗

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.Semantic proximity Read ↗

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Semantic proximity Read ↗

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Semantic proximity Read ↗

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis.Semantic proximity Read ↗

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.Semantic proximity Read ↗

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.Semantic proximity Read ↗

Genome-wide association studies of antidepressant outcome: a brief review.Semantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.Semantic proximity Read ↗

Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.